Management of immune thrombocytic purpura and acute coronary syndrome: A double-edged sword!

被引:6
作者
Shah, Ashish H. [1 ]
Anderson, Richard A. [2 ]
Khan, Ali Raza [3 ]
Kinnaird, Timothy D. [2 ]
机构
[1] Univ Hlth Network, Toronto, ON, Canada
[2] Univ Wales Hosp, Cardiovasc Med, Cardiff, Wales
[3] Univ Wales Hosp, Dept Haematol, Cardiff, Wales
关键词
Immune thrombocytopenic purpura; Coronary angioplasty; Stent thrombosis; Optical coherence tomography; INTRAVENOUS IMMUNOGLOBULIN; RISK; CLOPIDOGREL; THROMBOSIS; THERAPY;
D O I
10.1016/j.hjc.2014.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treating patients known to have immune thrombocytopenic purpura (ITP) presenting with acute coronary syndrome (ACS) pose challenges, especially if they undergo percutaneous coronary intervention and stenting, as they require certain period of dual antiplatelet medication based up on the type of stent been deployed. Co-existence of therapies to increase platelet number as well as anti-platelet efficacy at the same time appears contradictory; imbalance in antagonistic treatment approach of increasing platelet number to treat ITP and inhibiting their activity to treat ACS can result in life threatening complications. (C) 2016 Hellenic Cardiological Society. Publishing services by Elsevier B. V. This is an open access article under the CC BY-NC-ND license.
引用
收藏
页码:273 / 276
页数:4
相关论文
共 14 条
[1]   Medical progress: Immune thrombocytopenic purpura. [J].
Cines, DB ;
Blanchette, VS .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13) :995-1008
[2]   The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts [J].
Cohen, YC ;
Djulbegovic, B ;
Shamai-Lubovitz, O ;
Mozes, B .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (11) :1630-1638
[3]   Coronary revascularisation with Genous stent helps reduce the waiting time for lung resection [J].
Goldsmith, Ira R. A. ;
Smith, Dave .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2011, 40 (05) :1248-1249
[4]  
JY W, 1992, J LAB CLIN MED, V119, P334
[5]   Intravenous immunoglobulin-associated arterial and venous thrombosis;: report of a series and review of the literature [J].
Marie, I. ;
Maurey, G. ;
Herve, F. ;
Hellot, M. -F. ;
Levesque, H. .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (04) :714-721
[6]  
Niwa K, 1995, CORONARY ARTERY DIS, V6, P857
[7]   The risk of thrombosis in essential thrombocythemia and polycythemia vera [J].
Pearson, TC .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :16-21
[8]  
Rand ML, 1998, ACTA PAEDIATR, V87, P57
[9]   EFFECT OF HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN THERAPY ON BLOOD RHEOLOGY [J].
REINHART, WH ;
BERCHTOLD, PE .
LANCET, 1992, 339 (8794) :662-664
[10]   Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot GENOUS trial [J].
Sangiorgi, Giuseppe M. ;
Morice, Marie-Claude ;
Bramucci, Ezio ;
Ferlini, Marco ;
Grinfeld, Liliana ;
Petronio, Anna S. ;
Pierli, Carlo ;
Iadanza, Alessandro ;
Biondi-Zoccai, Giuseppe ;
Colombo, Antonio .
EUROINTERVENTION, 2011, 7 (07) :813-819